# The Impact of Behavioral Lifestyle Intervention on Inflammatory Cytokines in Older Adults Living With Type 2 Diabetes: A Feasibility Study

**Authors:** Rozmin Jiwani, Monica Serra, Sara Espinoza, Andrea Berndt, Darpan Patel

PMC · DOI: 10.1177/00469580241248126 · Inquiry: A Journal of Medical Care Organization, Provision and Financing · 2024-04-20

## TL;DR

This study shows that lifestyle changes can reduce inflammation and frailty in older adults with type 2 diabetes.

## Contribution

It demonstrates the feasibility of behavioral interventions in improving inflammatory markers and frailty in this population.

## Key findings

- The intervention improved frailty scores and reduced BMI in participants.
- Levels of IL-2, IFN-γ, and GM-CSF decreased after the 6-month intervention.
- A correlation was found between frailty, BMI, and inflammatory cytokines.

## Abstract

This study investigates the effects of a behavioral lifestyle intervention on inflammatory cytokines and frailty in older adults (≥ 65 years) with type 2 diabetes (T2D).

We conducted a single-arm, 6-month intervention supplemented with diet and activity self-monitoring technology. We assessed frailty using Fried criteria and quantified inflammatory cytokines (interleukin [IL]-2, IL-4, IL-6, IL-8, IL-10, granulocyte-macrophage colony-stimulating-factor [GM-CSF], interferon [IFN-γ], tumor necrosis factor [TNF-α]) using a multiplex assay. We used paired t-tests with significance at P < .05. We calculated the Spearman correlation and evaluated the relationship between frailty, BMI, and inflammatory cytokines.

Eighteen participants completed the study (mean ± SD: 71.5 ± 5.3 years; BMI: 34 ± 6 kg/m2). At baseline, we had 4 frail, 13 pre-frail, and 1 non-frail participant. At 6 months, we observed the therapeutic effects of the intervention on frailty score, BMI, IL-2, IFN-y, and GM-CSF.

The study highlights the importance of behavioral lifestyle intervention in improving inflammatory cytokines and frailty in older adults.

## Linked entities

- **Proteins:** IL2 (interleukin 2), IL4 (interleukin 4), IL6 (interleukin 6), CXCL8 (C-X-C motif chemokine ligand 8), IL10 (interleukin 10), CSF2 (colony stimulating factor 2), IFNG (interferon gamma), TNF (tumor necrosis factor)
- **Diseases:** type 2 diabetes (MONDO:0005148)

## Full-text entities

- **Genes:** CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}
- **Diseases:** frailty (MESH:D000073496), T2D (MESH:D003924), inflammatory cytokines (MESH:D000080424)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11032638/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11032638/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC11032638/full.md

---
Source: https://tomesphere.com/paper/PMC11032638